清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 1897: Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers

抗体-药物偶联物 结合 聚糖 药品 抗体 医学 癌症 癌症研究 实体瘤 计算生物学 免疫学 药理学 生物 单克隆抗体 内科学 分子生物学 糖蛋白 数学分析 数学
作者
Juniper A. Scribner,Jennifer G. Brown,Thomas Son,Linda X. Jin,Carroll McKenzie,Viktoriya Nam,Curtis Bush,Dienis Quinonez,Delta Ford,Verlene Gonzalez,James K. Tamura,Sergey N. Gorlatov,Hua Li,Shelley Ruth Butler,Ezio Bonvini,Deryk T. Loo
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (6_Supplement): 1897-1897 被引量:2
标识
DOI:10.1158/1538-7445.am2024-1897
摘要

Abstract Introduction: Antibody-drug conjugates (ADCs) seek to increase the therapeutic window of potent cytotoxic agents by linking them with monoclonal antibodies (mAbs) to selectively deliver cytotoxic payloads to tumor cells. The effectiveness and safety of ADCs rely on both the mAb specificity, and the linker-payload employed. Several approved ADCs using microtubule inhibitor payloads are impacted by ocular adverse events that have been observed both preclinically and in patients. A class of linker-payloads incorporating topoisomerase 1 inhibitors (TOP1i) has emerged recently as an effective alternative to tubulin inhibitor-based ADCs. To date, TOP1i ADCs have not been associated with dose-limiting ocular toxicity seen with microtubule inhibitor payloads. Here we report the preclinical development of an ADAM9 (a disintegrin and metalloprotease domain 9)-targeted ADC that incorporates a novel glycan-linked TOP1i. ADAM9, a member of the ADAM family of multifunctional type 1 transmembrane proteins, plays a role in tumorigenesis and cancer progression and is overexpressed in multiple cancers, making it an attractive target for cancer treatment. Methods: MGC028 incorporates the cleavable linker-payload, bicyclononyne carbamoyl sulfamide Val-Ala-PABC exatecan (SYNtecan E™), site-specifically conjugated at asparagine 297 of the heavy chain through enzymatic glycan remodeling and metal-free click chemistry using Synaffix’s GlycoConnect™ technology. In vivo efficacy studies were performed in immunodeficient mice with ADAM9-expressing human tumor cell-line (CDX) or patient-derived (PDX) xenografts. A non-human primate toxicology study was conducted in which MGC028 was administered by 15-minute IV infusion every two weeks at dose levels of 22.5 and 55 mg/kg for a total of two doses. Results: MGC028 exhibited specific, dose-dependent in vivo antitumor activity toward ADAM9-positive CDX models representing gastric, lung, pancreatic and colorectal cancer, and head and neck squamous cell carcinoma. Furthermore, MGC028 demonstrated antitumor activity toward ADAM9-positive PDX models of lung and pancreatic cancer, and cholangiocarcinoma. MGC028 was well tolerated in a repeat-dose non-human primate toxicology study, up to 55 mg/kg, the highest dose level tested. Observations were limited to mild, reversible increases in liver enzymes, without microscopic correlates, and decreased lymphoid cellularity in the thymus. In particular, ocular toxicities were not observed. Conclusions: MGC028 exhibited potent antitumor activity in in vivo models representing various solid cancer indications and was well tolerated in non-human primates at exposure levels exceeding those required for antitumor activity. Our findings support continued investigation of MGC028 as an ADC therapeutic for the treatment of ADAM9-expressing solid cancers. Citation Format: Juniper A. Scribner, Jennifer G. Brown, Thomas Son, Linda Jin, Carroll McKenzie, Viktoriya Nam, Curtis Bush, Dienis Quinonez, Delta Ford, Verlene Gonzalez, James Tamura, Sergey Gorlatov, Hua Li, Shelley Butler, Ezio Bonvini, Deryk Loo. Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1897.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朴实乐天完成签到,获得积分10
11秒前
HelloBOB完成签到 ,获得积分10
12秒前
18秒前
俭朴竺完成签到,获得积分10
24秒前
liangyao完成签到,获得积分20
26秒前
Tardes关注了科研通微信公众号
32秒前
34秒前
朴实惜寒完成签到,获得积分10
42秒前
11完成签到 ,获得积分10
42秒前
44秒前
king完成签到 ,获得积分10
49秒前
wsj完成签到 ,获得积分10
50秒前
Tardes发布了新的文献求助10
51秒前
ss完成签到,获得积分10
54秒前
甜美的梦芝完成签到,获得积分10
56秒前
西瓜柠檬可乐完成签到 ,获得积分10
1分钟前
李煜琛完成签到 ,获得积分10
1分钟前
悦耳的竺完成签到 ,获得积分10
1分钟前
搜集达人的应助被冲冲冲采纳,获得10
1分钟前
大力的安阳完成签到 ,获得积分10
1分钟前
无花果的应助被ZLPY采纳,获得30
1分钟前
1分钟前
1分钟前
刘亚梅完成签到 ,获得积分10
1分钟前
醉熏的小凡完成签到,获得积分10
1分钟前
冲冲冲发布了新的文献求助10
1分钟前
apt完成签到 ,获得积分10
1分钟前
1分钟前
忧伤的白秋完成签到,获得积分10
1分钟前
1分钟前
lx完成签到 ,获得积分10
1分钟前
天天快乐的应助被hilufite采纳,获得10
2分钟前
nhzz2023完成签到 ,获得积分10
2分钟前
和谐如彤完成签到,获得积分10
2分钟前
nanjing01完成签到 ,获得积分10
2分钟前
如泣草芥完成签到,获得积分10
2分钟前
Jessie完成签到,获得积分10
2分钟前
RZH发布了新的文献求助50
2分钟前
hy发布了新的文献求助10
2分钟前
笙歌完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780536
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697